Develops immunotherapies for cancer and infectious diseases.
Elicio Therapeutics, Inc. is a pioneering clinical-stage biotechnology firm dedicated to advancing a diverse pipeline of innovative immunotherapies tailored for cancer treatment.
At the forefront of its portfolio is ELI-002, a groundbreaking multivalent lymph node-targeted AMP peptide vaccine currently undergoing Phase II clinical trials. This candidate aims to combat seven driver mutations of the Kirsten rat sarcoma viral oncogene homolog (KRAS), a significant target in cancer therapy.
Additionally, Elicio Therapeutics is actively developing ELI-007 and ELI-008, both multivalent lymph node-targeted AMP peptide vaccines. ELI-007 targets mutations of the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) found in solid tumors, while ELI-008 focuses on hotspot mutations of the tumor suppressor protein p53. These initiatives underscore the company's commitment to addressing critical unmet needs in oncology through innovative therapeutic approaches. Headquartered in Boston, Massachusetts, Elicio Therapeutics harnesses cutting-edge science and strategic partnerships to propel the future of cancer immunotherapy.